[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hospital-acquired-pneumonia-hap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hospital-acquired-pneumonia-hap":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100562420","long-term-alterations-of-host-microbiome-interactions-and-cardiovascular-and-respiratory-diseases-progression-after-pneumonia-100562420",false,"NCT06602934","Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia","Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia - the HOMI-LUNG Project - Hospital-Acquired-Pneumonia","HOMI-LUNG-HAP","Inclusion Criteria:\n\nGroup A (patients with acute cardiac disease)\n\n* Male or female\n* Hospitalized for acute coronary syndrome for less than 7 days.\n* Informed consent from the patient\n* Person insured under a health insurance scheme\n\nGroup B (patients with chronic cardiovascular disease)\n\n* Male or female,\n* Undergoing coronary artery by-pass surgery\n* Hospitalized in intensive care unit for \\> 12 hours\n* Informed consent from the patient\n* Person insured under a health insurance scheme\n\nGroup C (patients at risk of CVRD without chronic cardiovascular disease)\n\n* Male or female,\n* Familial high levels of cholesterol or triglycerides\n* With no personal history of CVRD, with a recent negative cardiac exercise test (last test inferior to 12 months)\n* Follow-up for lipid abnormalities at high risk of CVRD events\n* Informed consent from the patient\n* Person insured under a health insurance scheme\n\nGroup D (patients with HAP)\n\n* Male or female\n* With one or more risk factors for CVD among:\n\nAge ≥ 65 years old Smoking, Abnormal lipidic levels, High blood pressure, Obesity, Diabetes mellitus, Chronic kidney disease\n\n* Cured from mechanically ventilated HAP during the current hospitalization\n* Informed consent from the patient or relatives\n* Person insured under a health insurance scheme\n\nExclusion Criteria:\n\n* Groups A, B, C and D\n* Age \\\u003C80 years old\n* Immunosuppression pre-existing to the index hospitalisation, defined as lymphopenia; 500 elements\u002Fmm3, haematologic cancer, aplasia, chemotherapy\u002Fradiotherapy for cancer within 3 months prior to the inclusion, or anti-graft rejection drug.\n* Pregnant women, breastfeeding women.\n* Adults under guardianship or trusteeship.\n* Low probability of survival at day 28.\n\n  o Groups A, B, C\n* Community-acquired pneumonia or Hospital-acquired pneumonia within the last year.","ALL","18 Years","80 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","The HOMI-LUNG - HAP study is part of the HOMI-LUNG project, funded by the Horizon Europe program. The \"HOMI-LUNG\" project is an international, interdisciplinary project that aims to better understand the causal links between respiratory tract infections (i.e. pneumonia) and the progression of cardiovascular disease. More specifically, the project aims to quantify the burden of cardiovascular disease after pneumonia and assess patients; acceptability of long-term health alterations, as well as to define pneumonia endotypes with distinct pathobiological mechanisms associated with exacerbation of cardiovascular disease.",[28,29],"Hospital Acquired Pneumonia (HAP)","Cardiovascular and Respiratory Disease",[31,32,33],"Hospital-acquired pneumonia","Cardiovascular and respiratory diseases","Respiratory microbiome","RECRUITING","2026-06-02",{"date":37,"type":38},"2026-06-04","ACTUAL",{"date":40,"type":38},"2025-01-02",{"date":42,"type":22},"2029-01-01",{"name":44,"class":45},"Nantes University Hospital","OTHER",5,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":5},"100613589","real-world-effectiveness-of-aztreonam-avibactam-against-mbl-producing-cre-100613589","NCT07268560","Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE","Aztreonam-Avibactam Real World Study Against Metallo-β-lactamase-Producing Carbapenem-Resistant Enterobacterales","AWARE","Inclusion Criteria:\n\n* 1\\. Age 18 years or older 2. Hospitalized with a diagnosis of confirmed cIAI or HAP\u002FVAP 3. Confirmed infection with MBL-producing CRE 4. Received on label use of ATM-AVI treatment for ≥24 hours 5. Informed consent will be obtained or waived.\n\nExclusion Criteria:\n\n* 1\\. Confirmed or suspected infection caused by Gram-negative species not expected to respond to ATM-AVI 2. Currently enrolled in an interventional clinical tria",{"count":56,"type":22},100,"OBSERVATIONAL","Why This Study is Needed Some bacterial infections have become resistant to common antibiotics, making them very difficult to treat. This is a growing and serious health problem. A new combination drug, Aztreonam-Avibactam (we'll call it ATM-AVI), has been developed to fight these tough bacteria.\n\nThis new drug was recently approved for use in Europe (April 2024), the United States (February 2025), and China (June 2025). Because it is so new, there is very little information available, especially in China, on how well it works for real patients outside of initial testing.\n\nThis lack of real-world experience means we don't know enough about:\n\n* How effective it is for typical patients in China.\n* The types of patients and infections it is used for.\n* How it affects a patient's time in the hospital. This study aims to fill these gaps by looking at how ATM-AVI performs in Chinese hospitals, which will help doctors better treat these dangerous infections and improve patient recovery.\n\nWhat the Study Aims to Find Out\n\nMain Goal:\n\nTo see how well ATM-AVI works for adult patients in China with these specific antibiotic-resistant infections.\n\nOther Goals:\n\nTo gather more details about:\n\n* How patients are responding to the treatment at different points (e.g., after 5 days, at the end of treatment, and at a follow-up check).\n* Whether the bacteria causing the infection are cleared.\n* How the treatment affects the patient's hospital stay and use of resources.\n* The number of patients who, unfortunately, pass away during or after treatment.\n* The characteristics of the patients (like age) and their infections.\n* How doctors are using this new drug and if it's used alongside other antibiotics.\n\nHow the Study Will Work This is an observational study that will be conducted in about 30 hospitals across China. We plan to include around 100 adult patients who were hospitalized with these tough infections and received the new drug, ATM-AVI, for at least one full day.\n\nThe study will run from October 2025 to June 2027. We will look at both past (retrospective) and future (prospective) patients. For past patients, we will review their existing medical records. For future patients, we will ask for their permission (informed consent) before collecting any information.\n\nWe will collect information from patient records, such as:\n\n* Basic patient details and the nature of their infection.\n* How and when the ATM-AVI drug was used.\n* Details about their hospital stay.\n* The results of their lab tests. A doctor will assess and record how each patient is doing at key points: 5 days after starting the drug, at the end of the treatment, and at a follow-up check to see if the infection is cured.",[60,61,62],"Complicated Intra-Abdominal Infections, cIAIs","Hospital-acquired Pneumonia (HAP)","Ventilator-Associated Pneumonia (VAP)","2026-03-19",{"date":65,"type":38},"2026-03-23",{"date":67,"type":38},"2025-12-25",{"date":69,"type":22},"2027-07-31",{"name":71,"class":45},"Sir Run Run Shaw Hospital"]